tbuckley/cabot-search huggingface dataset:
Abstract 12145: Cardiac Magnetic Resonance Late Gadolinium Enhancement is Associated With Ventricular Elastance That May Predict Latent Ventricular Dysfunction After Fontan Procedure
Authors: Michihiro Okuyama, Shuta Ishigami, Daiki Ousaka, Junko Kobayashi, Sadahiko Arai, Shingo Kasahara, Shunji Sano, Hidemasa Oh
Journal: Circulation (2014)

Backgrounds: Systemic right ventricular circulation after Fontan procedures is known to have late hemodynamic complications. Although a number of studies have investigated the factors that may impact on survival, postoperative outcomes after palliations remain to be elucidated. Objective: The purpose of this study is to investigate the prognostic value of myocardial fibrosis identified by cardiac magnetic resonance imaging (cMRI) in patients with single ventricular physiology. Methods: Consecutive 23 patients undergoing Fontan procedures were prospectively scheduled to have cMRI study with late gadolinium enhancement (LGE) imaging and ventricle circumferential strain measurement before and 4 months after Fontan operation. Results: Of 23 patients (mean age 3.3±0.9 years), 7 were positive for LGE (LGE+) and median percent LGE was 3.0% (interquartile range 3.0% to 7.5%). Pre-Fontan examinations revealed that patients with LGE+ showed an increase in end-diastolic volume index (139.7±26.8 ml/BSA vs. 113.3±20.9 ml/BSA; P=0.02) and end-systolic volume index (ESVI: 99.9±32.2 ml/BSA vs. 70.8±20.0 ml/BSA; P=0.01) compared with those without LGE (LGE-). In contrast to LGE- group, LGE+ patients showed lower global circumferential strain (4.1±2.3% vs. 7.9±2.7%, P=0.006), decreased ejection fraction (EF: 29±9.1% vs. 38±8.7%; P=0.04), and reduced end-systolic elastance (1.1±0.3 mm Hg/ml/m2 vs. 1.7±0.5 mm Hg/ml/m2). In addition, LGE+ group had higher levels of BNP (91.0±72.4 pg/ml vs. 30.9±44.0 pg/ml, P=0.02) and New York University Pediatric Heart Failure Index (10.9±3.3 vs. 7.8±1.1, P=0.02) than LGE- group. This was validated by positive correlations between the area of LGE versus ESVI (r=0.85, P=0.01) and BNP levels (r=0.82, P=0.02), respectively. At 4 months after Fontan procedure, LGE- group showed higher EF (37.5±8.6% vs. 24.0±8.9%, P=0.02) compared with those in LGE+ patients, and increased global circumferential strain (6.5±2.0% to 7.4±2.7%, P=0.04). Conclusion: LGE identified by cMRI before operation may be associated with lower ventricular elastance that resulted in poorer functional recovery after staged palliation. This novel strategy may provide a prognostic value of latent myocardial dysfunction after Fontan procedure.
Abstract 18309: The Effects of Repetitive Transendocardial CD34+ Cell Therapy in Dilated Cardiomyopathy Patients
Authors: Bojan Vrtovec, Gregor Poglajen, Gregor Zemljic, Matjaz Sever, Marko Cukjati, Sabina Frljak, Andraz Cerar, Renata Okrajsek, Peter Cernelc, Francois Haddad, Joseph C Wu
Journal: Circulation (2016)

Introduction: The clinical effects of repetitive cell therapy in heart failure have not been studied yet. Hypothesis: We investigated whether repetitive administration of CD34+ cells is superior to...
TCT-591 Hypoalbuminemia increases periprocedural stroke in transcatheter aortic valve replacement: a retrospective single-center case-control analysis
Authors: Dominique Monlezun, Adam Whigham, Patrick Byrnes, Abhijeet Dhoble, Richard Smalling, Pranav Loyalka, Biswajit Kar, Tom Nguyen, Anthony Estrera, Prakash Balan
Journal: Journal of the American College of Cardiology (2018)
Alcohol is blamed for one in 20 deaths as reduced consumption remains elusive
Authors: Melanie Newman
Journal: BMJ (2018)

Europeans drank less alcohol in 2016 than in 2005 but remain the biggest consumers in the world, each drinking 9.8 L a year, says the World Health Organization’s latest report on global alcohol consumption.1

Globally, no progress has been made in reducing per capita alcohol consumption, which is forecast to increase over the next 10 years, the report said.

Some three million deaths worldwide (5.3% of all deaths) resulted from alcohol use in 2016, it added. While this is a reduction from the 2012 estimate of 3.3 million, it still represents one in 20 deaths. Over three quarters of these deaths were among men.

China, where alcohol consumption per capita increased from 4.1 L …
Clinical characteristics and outcomes associated with molecular status and treatment with vemurafenib in metastatic melanoma (MM) in a real-world setting: Comparison of four groups.
Authors: Dorota Malgorzata Kwapisz
Journal: Journal of Clinical Oncology (2018)

e21558 Background: BRAF and NRAS are frequently mutated in melanoma. The purpose of the study is to compare clinicopathological characteristics and outcomes patients (pts) with MM depending on molecular status, taking account treatment with vemurafenib. Methods: 323 consecutive pts with MM forming 4 groups were analysed: NRAS+ (NRAS), BRAF+ treated with vemurafenib (BRAF-VEM), BRAF+ untreated with vemurafenib (BRAF-UT), wild-type (WT). The presence of BRAF gene V600 mutation was evaluated by the cobas 4800 BRAF V600 Mutation Test, and NRAS mutation by sequencing method (codons 12, 13, 61). Two-, three-, and four-group comparisons were performed. All data since metastatic disease was diagnosed were collected prospectively. Results: 46 pts had NRAS mutation, 73 were WT. 115 of 204 pts with BRAF+ melanoma were treated with vemurafenib. Pts with a BRAF mutation were diagnosed at a younger age (p = 0.0005). In NRAS was higher percentage of pts with elevated LDH at the time of PM excision than in BRAF+ (p < 0.0005). At the time of PM diagnosis N0/N1 was noted in the highest percentage in BRAF+ and N2/N3 in NRAS (p = 0.036). Lymphadenectomy was performed in the highest percentage in NRAS, and in the lowest among WT (p < 0.0005). MM developed in NRAS at the latest. BRAF+ MM had the highest number of metastatic localisations (different organs) at the time of metastatic disease diagnosis (p < 0.018). At the time of analysis 225 pts have died. The highest percentage of deaths was noted in NRAS (85%) and the lowest in WT (56%; p < 0.0005). Mutation status was associated with overall survival (OS) from the PM excision (log rank test; p = 0.0053). BRAF-UT had shorter median OS (2.1 yrs) than NRAS (3.0 yrs) or WT (3.9 yrs) or BRAF-VEM (4.6 yrs). However, when OS was calculated from MM diagnosis the shortest OS had NRAS. Among NRAS, OS was longer for women (p = 0.019). Conclusions: This study support the idea that targeted therapy can spectacularly improve survival and change the fate of pts with poor prognosis (BRAF groups). Study also highlight the aggressiveness of NRAS MM and indicates the necessity of correct treatment of the PM as well as need for more effective therapies for NRAS+ MM.
Elucidating The Mechanisms Behind Defective Airway Epithelial Cell Repair In Childhood Asthma
Authors: T. Iosifidis, A. Buckley, E. Sutanto, K. Ling, L. Garratt, K. Looi, E. Kicic-Starcevich, K. Martinovich, F. Lannigan, P. Rigby, D. Knight, S. Stick, Anthony Kicic
Journal: American Journal of Respiratory and Critical Care Medicine (2015)
The study of clinicopathologic correlation with the expression level of 5-hydroxymethylcytosine in GIST.
Authors: Ching-Yao Yang, Chia-Han Lee, Jen-Chieh Lee, Jau-Yu Liau, Yung-Ming Jeng
Journal: Journal of Clinical Oncology (2018)

e23520 Background: Deregulation of 5-hydroxymethylcytosine (5-hmC) levels has been observed in many types of cancer. Furthermore, loss of 5-hmC expression seem to correlate with tumor invasiveness and poor prognosis. There were very rare reports about 5-hmc in GIST. The purpose of this study is to evaluate whether the expression level of 5-hmC in GIST correlate with the clinicopathologic profiles and influence the patients’ outcome. Methods: Tissue sections from 182 GIST patients operated between 2000 to 2012 were obtained for tissue microarray. The pathologic profile, clinical parameters, and outcome were collected. Expression level of 5-hmC was categorized as “0” for total loss of 5-hmC expression, “1+” for 1-10%, “2+” for 10-50%, and “3+” for diffuse 5-hmC expression ( > 50%). Clinicopathologic correlation with the expression levels of 5-hmC were calculated by univariate and multivariate analysis and Kaplan-Meier method. Results: In this cohort, 5-hmC expression level as 3+, 2+, 1+, 0 was 52%, 19%, 15%, 14%, respectively. The expression of 5-hmC has no difference in age, gender, and tumor sites. The expression level and high “3+” 5-hmc expression proportion are higher in larger tumor size, higher mitotic count, and in higher risk category either classified by NIH-Fletcher 2002 classification or by AFIP-Miettinen 2006 system. GIST patients with higher 5-hmC expression level has longer recurrence-free survival (p < 0.0001). 5-hmC positive (1+, 2+, or 3+) GIST patients has significant better 5-yr RFS (80%) compared 5-hmC negative GIST patients with 5-yr RFS 50%. (p = 0.0003) Patients with negative or low (1+) 5-hmC expression level have worse overall survival than patients with higher 5-hmC expression level (2+, 3+). After multivariate analysis, “3+” 5-hmC expression combined with tumor size less than 6 cm is one of the independent favorable prognostic factors for recurrence. Conclusions: GIST patients with low 5-hmC expression correlated unfavorable pathologic parameters, and have worse prognosis. Further analysis, and research on mechanism may be helpful for developing treatment strategy targeted on GISTs with deregulated 5-hmC.
Quantitative 3D Analysis of Coronary Wall Morphology in Heart Transplant Patients: OCT-Assessed Cardiac Allograft Vasculopathy Progression
Authors: Zhi Chen, Michal Pazdernik, Honghai Zhang, Andreas Wahle, Zhihui Guo, Helena Bedanova, Josef Kautzner, Vojtech Melenovsky, Tomas Kovarnik, Milan Sonka
Journal: Medical Image Analysis (2018)
TCT-509 Eighteen-month results of high-risk patients treated with ultrathin-strut biodegradable-polymer Orsiro DES. The Bioflow-III Satellite Italy Subgroups analysis.
Authors: Stefano Galli, Francesco Versaci, Carlo Briguori, Fabrizio Tomai, Arnaldo Poli, Carlo Vigna, Luigi My, Filippo Masi, Maurizio Turturo, Antonio Bartorelli
Journal: Journal of the American College of Cardiology (2018)
Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
Authors: Stacey Stein, Michael J. Pishvaian, Michael Sangmin Lee, Kyung-Hun Lee, Sairy Hernandez, Antonia Kwan, Bo Liu, William Grossman, Koho Iizuka, Baek-Yeol Ryoo
Journal: Journal of Clinical Oncology (2018)

4074 Background: Advanced HCC is a lethal cancer with a high unmet medical need. Single-agent immunotherapy with PD-L1/PD-1 blockade or treatment (Tx) with anti-angiogenic bevacizumab (bev; anti-VEGF) has shown modest activity in HCC. We hypothesized that the combination of atezolizumab (atezo; anti–PD-L1) + bev results in a greater clinical benefit due to the additional immunomodulatory effects of bev (increased DC maturation, enhanced T-cell infiltration, reduced MDSCs and Tregs in tumors), which create a more favorable tumor microenvironment that potentiates the efficacy of atezo. Methods: Patients (pts) with unresectable or metastatic HCC who were naive to systemic Tx were enrolled in a Phase Ib study cohort (NCT02715531). Pts received atezo (1200 mg) + bev (15 mg/kg) IV every 3 weeks until loss of clinical benefit or unacceptable toxicity. The primary objective was to assess the safety and tolerability of the combination. Secondary efficacy endpoints included ORR, PFS, DOR and time to progression (TTP) per RECIST v1.1; and OS. Results: As of the data cutoff (October 24, 2017), 26 pts were evaluable for safety. Tx-related all-grade AEs occurred in 21 pts (81%). Tx-related grade 3-4 AEs were seen in 9 pts (35%), most commonly hypertension (n = 5 [19%]). No grade 5 AEs were observed. Two pts (8%) experienced 3 Tx-related grade 3 serious AEs (autoimmune encephalitis, mental status change and intra-abdominal hemorrhage). Immune-related AEs requiring corticosteroid Tx occurred in 3 pts (12%). Among 21 efficacy-evaluable pts (minimum follow-up, 16 wk; median survival follow-up, 8.3 mo), confirmed partial responses occurred in 13 pts (62%) regardless of HCC etiology, region (Asia or US), baseline a-fetoprotein levels (≥ or < 400 ng/mL) or extrahepatic spread of tumor. The median estimates for PFS, DOR, TTP and OS have not yet been reached. Conclusions: The combination of atezo + bev is safe and well tolerated; no new safety signals were identified beyond the established safety profile for each agent. The confirmed response rate of 62% suggests that atezo + bev in combination has synergistic clinical activity. Expansion of this HCC cohort and evaluation of atezo + bev in a Phase III study are under way. Clinical trial information: NCT02715531.
A phase III open label randomized study to compare the efficacy of lenalidomide-rituximab vs bendamustine-rituximab in treatment naive follicular lymphoma.
Authors: Susanta Kumar Paikaray, Ajay Gogia, Lalit Kumar, Atul Sharma, Ahitagni Biswas, Mehar C Sharma, Sanjay Thulker, Rakesh Kumar, Sreenivas Vishnubhatla, Saumyaranjan Mallick
Journal: Journal of Clinical Oncology (2018)

e19552 Background: Bendamustine-rituximab (BR) is the preferred regimen for treatment naïve follicular lymphoma (FL).Lenalidomide-rituximab (LR), a chemotherapy-free protocol has shown good response rate in advanced FLin phase II trials. These regimens have never been compared head to head in a randomized controlled trial for treatment naïve FL. Methods: This phase III open label randomised controlled trial was conducted at our center from January 2016 to December 2017.Treatment naïve patients with age more than 18 years, ECOG PS ≤2, who were diagnosed with FL (Stage II–IV)were included in our study.Patients were randomised in 1:1 ratio to receive six cycles of BR(bendamustine 90 mg/m2 d1-2 and rituximab 375mg/m2 d1) every 4 weeks or LR (lenalidomide 20 mg d1-21 and rituximab 375 mg/m2) every 4 weeks.The primary endpoint was complete response rate (CRR)and secondary endpoints were overall response rate(ORR) and toxicity. The trial is registered with Clinical Trials Registry-India (CTRI/2016/05/006904). Results: We enrolled 23 patients, 11patients received BR and 12 patients received LR. At a median follow up of 15 months, theCRRwas 63.6 %( n = 7) and 16.6% ( n = 2) in BR and LR arm respectively (p = 0.03). The ORR was 81.8% (n = 9) and 83.3 %( n = 10) in BR and LR arm respectively (p = 1.0). BR was better tolerated than LR with lower rates of all grade of toxicities (54% vs 92%),anemia (0% vs 33.3%), skin toxicity (18% vs 33%), diarrhoea (18% vs 42%), vomiting(9% vs 25%)and nephrotoxicity (0% vs 17%). There was no significant difference in grade 3 or 4 toxicities between BR and LR arm (27% vs 25%). Conclusions: The ORR was similar in both the arms, however, CRR were significantly higher with BR arm. BR was better tolerated than LR. Clinical trial information: CTRI/2016/05/006904.
Safety analysis of a phase III randomized trial comparing FOLFOX + Bevacizumab vs FOLFOXIRI + Bevacizumab as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 circulating tumor cells (CTCs) (VISNÚ-1 TTD TRIAL).
Authors: A. Gomez, Jose María Vieitez, Silvia Gil, Antonieta Salud Salvia, Begoña Graña Suárez, Pilar Garcia Alfonso, Eva Martínez de Castro, Guillermo Alfonso Quintero Aldana, Juan J Reina, Encarnación González Flores, Mercedes Salgado Fernández, Mercedes Rodríguez Garrote, Ma. José Flor Oncala, Maria Jose Safont, Adelaida La Casta Munoa, Rafael Lopez, Guillot Monica, Beatriz García-Paredes, Eduardo Diaz-Rubio, Enrique Aranda
Journal: Journal of Clinical Oncology (2018)

3536 Background: FOLFOXIRI plus bevacizumab has demonstrated a survival benefit compared with FOLFIRI plus bevacizumab (TRIBE Lancet Oncol 2015) in first-line mCRC. This schedule is not routinely recommended in all patient groups due to toxicity. VISNÚ-1 trial compared FOLFOX + Bevacizumab (arm A) vs FOLFOXIRI + Bevacizumab (arm B) in non-elderly patients(p) with ≥ 3CTCs at baseline as a poor prognostic factor. Preliminary safety analysis is presented here. Methods: This is an open, multicentric, randomized phase III trial. Patients aged ≤ 70 years, ECOG 0-1 were randomized to arm A or arm B, stratified per KRAS mutation. The data presented here were generated from a snapshot of the database from Oct-31st-2017. Results: 350 p have been included in the study, 347 p were available for safety analysis. General characteristics in arms A and B: Median age (59 vs 60.5 years), gender (Male/Female: 67.2/32.8 vs 69.4/30.1%), ECOG 0/1 (48/52 vs 47/53%), primary tumor unresected (32.2 vs 37.1%), previous adjuvant chemotherapy (4.0 vs 5.3%). Most common grade ≥3 toxicities and treatment modifications are shown in table 1. Only neutropenia, asthenia, diarrhea and mucositis were more frequent in arm B. Fourteen patients dead due to treatment-related adverse events (6 in the FOLFOX- BEV arm and 8 in the FOLFOXIRI-BEV arm): 7 sepsis, 5 bowel perforation, 2 pulmonary toxicity). Conclusions: In our study, the use of FOLFOXIRI + Bev in mCRC did not result in an increase in treatment delays, dose reductions or treatment interruptions as compared with FOLFOX+Bev despite an increased incidence of neutropenia, diarrhea, asthenia and mucositis. Clinical trial information: NCT01640405. FOLFOX+BEV (N=177) FOLFOXIRI+BEV (N=173) Treatment N (%) N (%) Delayed No 29 (16.4) 23 (13.5) Yes 148 (83.6) 147 (86.5) Dose Reductions No 83 (46.9) 62 (36.5) Yes 94 (53.1) 108 (63.5) Interrupted No 75 (42.4) 74 (43.5) Yes 102 (57.6) 96 (56.5) Adverse Events related to treatment (%) % % Grade ≥3 62.2 76.5 Neutropenia 24.3 34.7 Asthenia 6.2 14.7 Diarrhea 5.1 20 Neurotoxicity 21.5 18.8 Mucositis 3.4 8.8 Hypertension 3.4 3.6 Bowel perforation 4.5 2.35
Pathologic findings in reduction mammoplasty procedures identified by natural language processing of breast pathology reports: A surrogate for the population incidence of cancer and high risk lesions.
Authors: Francisco Acevedo, Rong Tang, Suzanne Coopey, Adam Yala, Regina Barzilay, Clara Li, Amy Colwell, Anthony Guidi, Curt Cetrulo, Judy Ellen Garber, Barbara L. Smith, Michele Gadd, Michelle Connolly Specht, Thomas Gudewicz, Danielle Braun, Giovanni Parmigiani, Kevin S. Hughes
Journal: Journal of Clinical Oncology (2018)

e13569 Background: Breast reduction surgery removes a random sample of breast tissue in otherwise asymptomatic women and thus provides a method to evaluate the background incidence of breast pathology in this population. Our goal was to identify the rate of atypical breast lesions and of cancers women of various ages in the largest mammoplasty cohort reported to date. Methods: With institutional Review Board (IRB) approval, pathologic reports from patients undergoing bilateral mammoplasty procedures in 5 institutions were analyzed using Natural Language Processing, verified by human review. Patients with a previous history of cancer were excluded. Results: A total of 5121 patients were included. The median age was 41 years (range 13-85), while the median age was higher in patients with any incidental finding when compared to patients with normal pathologic report (51 vs 39, p = 0.0001). Pathological findings were detected in 7.1% of procedures (table 1). Benign high-risk lesions (LCIS and atypical hyperplasia) were found in 319 patients (6.2%). Invasive carcinoma and DCIS was detected in 19 (0.4%) and 25 (0.5%) patients, respectively. The rate of atypias and cancers increased with age (table 2). Conclusions: The rate of abnormal findings in asymptomatic patients undergoing mammoplasty was 7.1%, and showed increasing incidence with older age. As only a random sample of breast tissue was removed at operation, our findings likely underestimate the incidence of these findings in normal women TABLE 1. Distribution of pathologic findings in our cohort. All Patients with Pathologic Lesions (n = 363) Pathologic Lesion Number of Patients affected % (from the total) Cancer Invasive 19 0.37% Ductal Carcinoma In-Situ 25 0.49% Lobular Carcinoma In-Situ 60 1.17% Severe Atypical Ductal Hyperplasia 14 0.27% Atypical Ductal Hyperplasia 119 2.32% Atypical Lobular Hyperplasia 126 2.46% TABLE 2. Rate of Pathologic Findings according to age AGE NUMBER ALL PATHOLOGIC LESIONS % 10 - 20 354 2 0.6% 21 - 30 1032 9 0.9% 31 - 40 1056 34 3.2% 41 - 50 1258 106 8.4% 51 - 60 968 152 15.7% 61 - 70 325 52 16.0% 71 - 80 53 7 13.2% 81 - 90 3 0 0.0%
Use of electronic cigarettes (e-cigarettes) by cancer patients.
Authors: Samuel Lewis Cooper, Sarah Annand, Kenneth Michael Cummings, David T. Marshall, Jennifer L. Harper, Joseph M. Jenrette, Anand K. Sharma, Georges El Nahas, Graham W. Warren
Journal: Journal of Clinical Oncology (2018)

e13545Background: Few studies have reported on contemporary electronic cigarettes (EC) use patterns in cancer patients presenting for cancer treatment recommendations. Methods: A standardized 13 it...
P04.74 Preclinical evaluation of combinations targeting the DNA damage response in 2D and 3D models of glioblastoma stem cells
Authors: O Rominiyi, N Gomez-Roman, N Lad, Y Al-Tamimi, D A Jellinek, A J Chalmers, T A Carroll, B Chen, S J Collis
Journal: Neuro-Oncology (2018)

Despite surgical resection followed by DNA-damaging adjuvant therapies, glioblastoma remain incurable. Increasing evidence demonstrates that aberrations within the DNA damage response (DDR) of cancer stem cells contribute to treatment resistance. We have previously shown that the Fanconi Anaemia (FA) pathway, a key DDR process, remains inactive in normal brain but is re-activated in glioblastoma, making it an appealing foundational target for cancer-specific combination therapies. Since intratumoural heterogeneity in glioblastoma and inherent capacity for functional redundancy within DDR networks are established concepts - we aimed to determine whether combined and hypothesis-driven targeting of the FA pathway along with interconnected DDR processes could form a basis for effective multimodal therapies. Bioinformatic analysis of mRNA expression data (REMBRANDT database) was used to confirm the relevance of FA pathway activity in glioma. Subsequently, immunofluorescence and cell viability assays were used to validate and establish the therapeutic potential of novel FA pathway inhibitors (nFAPi) and inhibition of related DDR targets in established cell models. Finally, combinations targeting the DDR were optimised using immunoblotting, and assessed using clonogenic survival in 2D and novel 3D patient-derived glioblastoma stem cell models. High expression of downstream FA pathway genes is strongly associated with poor survival (-17.1% 5-year OS, n=329, Log-rank, P<0.0001) and is a feature of more aggressive tumour biology (log2-relative expression, glioblastoma vs WHO Grade I-III gliomas: 7.18 ± 0.02 vs 7.08 ± 0.02, unpaired t-test, P=0.0009). Furthermore, FAPi and nFAPi were confirmed to attenuate key markers of FA pathway activity. Of translational importance, nFAPi sensitised glioblastoma cells to temozolomide (comparison of fits F value 63.7, P<0.0001). Inhibitors of PARP1 (PARPi) and ATR also demonstrated potential as temozolomide-sensitising agents. Furthermore, combined FAPi and PARPi significantly reduced cell viability (F value 13.0, P<0.0001) and enhanced radiosensitisation in G7 & G1 patient-derived 3D models with sensitiser enhancement ratios (SER0.37) of 1.51 (1.50–1.51, 95% CI) and 1.57 (1.52–1.61), respectively. Quantification of α/β ratio enhancement suggests combined DDR targeting may fundamentally alter the response of glioblastoma stem cells to irradiation (IR) - ratios (G7): DMSO 2.5 (1.6–2.9), FAPi 6.4 (5.8–7.7), PARPi 7.4 (6.4–10.1), combination 23.1 (14.6–108.5). Simultaneously targeting the FA pathway and interconnected DDR processes in glioblastoma represents a promising therapeutic strategy. Early mechanistic studies suggest this approach augments DNA damage and enhances IR-induced cell cycle arrest in G2/M, however further preclinical evaluation is ongoing.